DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites Journal Article


Authors: Calina, T. G.; Perez, E.; Grafenhorst, E.; Benhamida, J.; Schallenberg, S.; Popescu, A.; Koch, I.; Janik, T.; Chen, B.; Ihlow, J.; Roessler, S.; Goeppert, B.; Sinn, B.; Bahra, M.; Calin, G. A.; Taube, E. T.; Pelzer, U.; Neumann, C. C. M.; Horst, D.; Knutsen, E.; Capper, D.; Dragomir, M. P.
Article Title: DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites
Abstract: Background: We have recently constructed a DNA methylation classifier that can discriminate between pancreatic ductal adenocarcinoma (PAAD) liver metastasis and intrahepatic cholangiocarcinoma (iCCA) with high accuracy (PAAD-iCCA-Classifier). PAAD is one of the leading causes of cancer of unknown primary and diagnosis is based on exclusion of other malignancies. Therefore, our focus was to investigate whether the PAAD-iCCA-Classifier can be used to diagnose PAAD metastases from other sites. Methods: For this scope, the anomaly detection filter of the initial classifier was expanded by 8 additional mimicker carcinomas, amounting to a total of 10 carcinomas in the negative class. We validated the updated version of the classifier on a validation set, which consisted of a biological cohort (n = 3579) and a technical one (n = 15). We then assessed the performance of the classifier on a test set, which included a positive control cohort of 16 PAAD metastases from various sites and a cohort of 124 negative control samples consisting of 96 breast cancer metastases from 18 anatomical sites and 28 carcinoma metastases to the brain. Results: The updated PAAD-iCCA-Classifier achieved 98.21% accuracy on the biological validation samples, and on the technical validation ones it reached 100%. The classifier also correctly identified 15/16 (93.75%) metastases of the positive control as PAAD, and on the negative control, it correctly classified 122/124 samples (98.39%) for a 97.85% overall accuracy on the test set. We used this DNA methylation dataset to explore the organotropism of PAAD metastases and observed that PAAD liver metastases are distinct from PAAD peritoneal carcinomatosis and primary PAAD, and are characterized by specific copy number alterations and hypomethylation of enhancers involved in epithelial-mesenchymal-transition. Conclusions: The updated PAAD-iCCA-Classifier (available at https://classifier.tgc-research.de/) can accurately classify PAAD samples from various metastatic sites and it can serve as a diagnostic aid. © The Author(s) 2024.
Keywords: immunohistochemistry; controlled study; human tissue; aged; middle aged; major clinical study; genetics; liver neoplasms; pancreatic neoplasms; metastasis; diagnosis, differential; clinical assessment; differential diagnosis; carcinoma, pancreatic ductal; cohort analysis; pathology; validation study; breast neoplasms; tumor marker; dna methylation; liver metastasis; epigenetics; breast tumor; liver tumor; diagnosis; pancreas tumor; brain metastasis; neoplasm metastasis; bile duct carcinoma; bile duct neoplasms; cholangiocarcinoma; tissue microarray; carcinomatous peritonitis; metastatic breast cancer; dna extraction; pathway analysis; copy number variation; bile duct tumor; molecular diagnosis; pancreatic ductal adenocarcinoma; epithelial mesenchymal transition; pancreatic ductal carcinoma; measurement accuracy; humans; human; male; female; article; biomarkers, tumor; cancer of unknown primary; anatomical location
Journal Title: Clinical Epigenetics
Volume: 16
ISSN: 1868-7075
Publisher: BioMed Central Ltd.  
Date Published: 2024-11-10
Start Page: 156
Language: English
DOI: 10.1186/s13148-024-01768-x
PUBMED: 39523345
PROVIDER: scopus
PMCID: PMC11550539
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors